Tokyo Tape
Sign in
← CellSeed

Annual report

7776.TEDINET S100T4XQ
Period2023-01-01 → 2023-12-31
Filed2024-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 13 passed
Key figures · 100
MetricValuePeriodScopeSource row
Revenue¥190m2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥126m2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥162m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥199m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥276m2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Operating income−¥698m2023-01-01 → 2023-12-31StandaloneOperating income
Operating income−¥743m2022-01-01 → 2022-12-31StandaloneOperating income
Ordinary income−¥710m2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income−¥754m2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥887m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥866m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥745m2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥729m2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥786m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥787m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥846m2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Profit before tax−¥759m2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Net income (owners)−¥915m2021-01-01 → 2021-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥784m2020-01-01 → 2020-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥782m2019-01-01 → 2019-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income−¥847m2023-01-01 → 2023-12-31StandaloneProfit loss
Net income−¥760m2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥913m2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income−¥768m2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income−¥783m2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Total assets¥2.5bnat 2023-12-31StandaloneAssets
Total assets¥1.5bnat 2022-12-31StandaloneAssets
Total assets¥1.4bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.4bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.8bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.8bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.5bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.5bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥301mat 2023-12-31StandaloneLiabilities
Total liabilities¥366mat 2022-12-31StandaloneLiabilities
Net assets / equity¥2.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.2bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.0bnat 2021-12-31dStandaloneNet assets
Net assets / equity¥1.0bnat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.5bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.6bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.3bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.4bnat 2019-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.2bnat 2023-12-31StandaloneCash and deposits
Cash and deposits¥1.1bnat 2022-12-31StandaloneCash and deposits
Cash & equivalents¥2.2bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥847mat 2021-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥931mat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.5bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.1bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥779m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥718m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥817m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥701m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥578m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥56m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥62m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥110m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥13m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥133m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.8bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥882m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥397m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥721m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-29.432023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.312022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.182021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.082021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-55.312020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-54.192020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-66.62019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-66.682019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥68.08at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥47.26at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥56.44at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥57.43at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥93.85at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥95.7at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥102.24at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥103.88at 2019-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio86.9%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio74.8%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio72.0%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio72.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio83.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio83.5%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio91.1%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio91.3%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued31,459,019at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued24,422,619at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued17,759,419at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued16,008,319at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued12,981,819at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees35at 2023-12-31StandaloneNumber of employees
Employees30at 2022-12-31StandaloneNumber of employees
Employees44at 2021-12-31dStandaloneNumber of employees
Employees40at 2020-12-31dStandaloneNumber of employees
Employees40at 2019-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2023-01-01 → 2023-12-31¥21m
Reconciling Itemsreconcilingsegment assetsat 2023-12-31¥2.3bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-12-31−¥197m
Cell Sheet Regenerative Medicinereportable segmentemployeesat 2023-12-3120 pure
Cell Sheet Regenerative Medicinereportable segmentrevenue2023-01-01 → 2023-12-31¥8m
Cell Sheet Regenerative Medicinereportable segmentrevenue external2023-01-01 → 2023-12-31¥8m
Cell Sheet Regenerative Medicinereportable segmentsegment assetsat 2023-12-31¥65m
Cell Sheet Regenerative Medicinereportable segmentsegment profit2023-01-01 → 2023-12-31−¥469m
Laboratory Consumables And Equipmentreportable segmentcapex2023-01-01 → 2023-12-31¥770,000
Laboratory Consumables And Equipmentreportable segmentdepreciation2023-01-01 → 2023-12-31¥8m
Laboratory Consumables And Equipmentreportable segmentemployeesat 2023-12-3110 pure
Laboratory Consumables And Equipmentreportable segmentrevenue2023-01-01 → 2023-12-31¥182m
Laboratory Consumables And Equipmentreportable segmentrevenue external2023-01-01 → 2023-12-31¥182m
Laboratory Consumables And Equipmentreportable segmentsegment assetsat 2023-12-31¥133m
Laboratory Consumables And Equipmentreportable segmentsegment profit2023-01-01 → 2023-12-31−¥32m
—segment totalcapex2023-01-01 → 2023-12-31¥770,000
—segment totaldepreciation2023-01-01 → 2023-12-31¥8m
—segment totalrevenue2023-01-01 → 2023-12-31¥190m
—segment totalrevenue external2023-01-01 → 2023-12-31¥190m
—segment totalsegment assetsat 2023-12-31¥198m
—segment totalsegment profit2023-01-01 → 2023-12-31−¥501m
Reconciling Itemsreconcilingcapex2022-01-01 → 2022-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥1.3bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-12-31−¥190m
Cell Sheet Regenerative Medicinereportable segmentrevenue2022-01-01 → 2022-12-31¥10m
Cell Sheet Regenerative Medicinereportable segmentrevenue external2022-01-01 → 2022-12-31¥10m
Cell Sheet Regenerative Medicinereportable segmentsegment assetsat 2022-12-31¥82m
Cell Sheet Regenerative Medicinereportable segmentsegment profit2022-01-01 → 2022-12-31−¥463m
Laboratory Consumables And Equipmentreportable segmentcapex2022-01-01 → 2022-12-31¥563,000
Laboratory Consumables And Equipmentreportable segmentdepreciation2022-01-01 → 2022-12-31¥8m
Laboratory Consumables And Equipmentreportable segmentrevenue2022-01-01 → 2022-12-31¥116m
Laboratory Consumables And Equipmentreportable segmentrevenue external2022-01-01 → 2022-12-31¥116m
Laboratory Consumables And Equipmentreportable segmentsegment assetsat 2022-12-31¥196m
Laboratory Consumables And Equipmentreportable segmentsegment profit2022-01-01 → 2022-12-31−¥90m
—segment totalcapex2022-01-01 → 2022-12-31¥563,000
—segment totaldepreciation2022-01-01 → 2022-12-31¥8m
—segment totalrevenue2022-01-01 → 2022-12-31¥126m
—segment totalrevenue external2022-01-01 → 2022-12-31¥126m
—segment totalsegment assetsat 2022-12-31¥277m
—segment totalsegment profit2022-01-01 → 2022-12-31−¥553m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 992
ItemContextValueUnit
Cash and cash equivalents (5-year summary)CurrentYearInstant_NonConsolidatedMember2163292000JPY
Number of employeesPrior4YearInstant_NonConsolidatedMember40
Number of employeesPrior3YearInstant_NonConsolidatedMember40
Number of employeesPrior2YearInstant_NonConsolidatedMember44
Number of employeesPrior1YearInstant_NonConsolidatedMember30
Number of employeesCurrentYearInstant_NonConsolidatedMember35
Average number of temporary workersPrior4YearInstant_NonConsolidatedMember－
Average number of temporary workersPrior3YearInstant_NonConsolidatedMember－
Average number of temporary workersPrior2YearInstant_NonConsolidatedMember－
Average number of temporary workersPrior1YearInstant_NonConsolidatedMember－
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember－
Total shareholder returnPrior4YearInstant_NonConsolidatedMember0.771
Total shareholder returnPrior3YearInstant_NonConsolidatedMember0.370
Total shareholder returnPrior2YearInstant_NonConsolidatedMember0.275
Total shareholder returnPrior1YearInstant_NonConsolidatedMember0.251
Total shareholder returnCurrentYearInstant_NonConsolidatedMember0.406
Total return on share price indexPrior4YearInstant_NonConsolidatedMember1.181
Total return on share price indexPrior3YearInstant_NonConsolidatedMember1.268
Total return on share price indexPrior2YearInstant_NonConsolidatedMember1.430
Total return on share price indexPrior1YearInstant_NonConsolidatedMember1.395
Total return on share price indexCurrentYearInstant_NonConsolidatedMember1.789
Number of employeesCurrentYearInstant_NonConsolidatedMember35
Average age years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember42.6
Average length of service years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember4.7
Average annual salary information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember6230936JPY
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember10
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember20
Number of employeesCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember5
Number of employeesCurrentYearInstant_NonConsolidatedMember35
Research and development expenses research and development activitiesCurrentYearDuration456414000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember36948000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember419466000JPY
Capital expenditures overview of capital expenditures etcCurrentYearDuration21632000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember31459019
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember31999019
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant31459019
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant31999019
Number of shares constituting one unitCurrentYearInstant_OrdinaryShareMember100
Number of shareholders national and local governmentsCurrentYearInstant_OrdinaryShareMember－
Number of shareholders financial institutionsCurrentYearInstant_OrdinaryShareMember2
Number of shareholders financial service providersCurrentYearInstant_OrdinaryShareMember37
Number of shareholders other corporationsCurrentYearInstant_OrdinaryShareMember97
Number of shareholders foreign investors other than individualsCurrentYearInstant_OrdinaryShareMember33
Number of shareholders foreign individual investorsCurrentYearInstant_OrdinaryShareMember65
Number of shareholders individuals and othersCurrentYearInstant_OrdinaryShareMember21408
Number of shareholders totalCurrentYearInstant_OrdinaryShareMember21642
Number of shares held number of units national and local governmentsCurrentYearInstant_OrdinaryShareMember－
Number of shares held number of units financial institutionsCurrentYearInstant_OrdinaryShareMember525
Number of shares held number of units financial service providersCurrentYearInstant_OrdinaryShareMember15911
Number of shares held number of units other corporationsCurrentYearInstant_OrdinaryShareMember8699

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 13 passed
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31mismatch
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass